EQT Fund Management S.a r.l. — 13F Holdings & Portfolio
CIK 1834239 · latest 13F-HR filed 2026-05-14
EQT Fund Management S.a r.l. manages $1.02B in 13F-reported U.S. long-equity assets across 5 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are WAY (58.77%), OCS (15.37%), EVMN (11.10%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 0, added to 2, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$1.02B
Long-equity book
5
Distinct positions
2026-03-31
Filed 2026-05-14
+1 / −0 / ↑2 / ↓1
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | WAYSTAR HLDG CORP | WAY | 946784105 | $599.8M | 58.77% | 24,879,437 | SH |
| 2 | OCULIS HOLDING AG | OCS | H5870P102 | $156.9M | 15.37% | 5,900,294 | SH |
| 3 | EVOMMUNE INC | EVMN | 30054Y107 | $113.3M | 11.10% | 4,929,633 | SH |
| 4 | PHARVARIS N V | PHVS | N69605108 | $96.7M | 9.48% | 3,424,609 | SH |
| 5 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $53.9M | 5.28% | 5,141,992 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | $1.02B | 5 | 0001193125-26-224227 |
| 2025-12-31 | 2026-02-11 | $1.11B | 4 | 0001193125-26-046725 |
| 2025-09-30 | 2025-11-14 | $1.86B | 4 | 0001193125-25-281778 |